KLRS Company Profile and Key Details

Kalaris Therapeutics Inc (NASDAQ:KLRS) closed at $9.66 USD, losing -$0.40 (-3.98%) from the previous close of $10.06. The stock is currently mid-range between its 52-week high and low $2.14 and $12.90. With a market capitalization of about $180.67 million, Kalaris Therapeutics Inc is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.05). Key stats such as the average daily volume over the past year has been around 181.55 thousand shares, volume is running light vs its 52-week average. Headquartered in Cambridge, MA, Kalaris Therapeutics Inc operates in the Healthcare sector and the Biotechnology industry. Led by CEO Andrew Oxtoby, the company employs approximately 14 people and listed since July 30, 2020. Kalaris Therapeutics Inc operates as a pharmaceutical company.

Kalaris Therapeutics Inc generated EPS of -$7.40 over the past year. Five-year average earnings growth is -6.86%. Wall Street analysts project EPS growth of 48.66% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $23.00 to $19.00. The high target offers 128.63% upside. The low target suggests 88.87% downside. The mean target is $20.67. This offers 105.47% upside. Kalaris Therapeutics Inc earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by -3.03%. The prior quarter beat by 19.61%. Over the last six quarters, Apple has recorded several small beats. These include -71.43% in November 12, 2024.

Kalaris Therapeutics Inc has 18.70 million shares outstanding. The public float is 4.31 million shares, elevated short interest at 2.34% of float. This equals 110.79 thousand shares. The short ratio is 2.22 days. Institutional investors hold 83.39% of the float. Insiders own 16.17%.

Short-term trend indicators are bearishly aligned (SMA20 35.13%, SMA50 65.71%, SMA200 101.04%). The stock’s 14-day RSI is 69.18 (firm momentum), while the ATR of 0.98 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -22.02% below its high and over 370.09% above its low. Average 10-day trading volume of 227.21 thousand shares is slightly above the 3-month average of 169.58 thousand, indicating heightened recent market interest.

Our AI price prediction model suggests that Kalaris Therapeutics Inc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 6.26%, with price expected at $10.69 by January 05, 2026, within a range of $9.71 to $11.68 3-Month Outlook: Projected rise of 416.5%, reaching $51.96 by March 20, 2026, with a range of $51.82 to $52.08. 1-Year Outlook: Projected gain of 342.25%, with price at $44.49 by December 22, 2026, within a range of $44.93 to $45.32.

Kalaris Therapeutics Inc last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $23.62. This means the shares are trading below this model’s fair value.

currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Kalaris Therapeutics Inc trading at a premium to the broader market with a P/E of -3.49. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $20.67, suggesting 105.47% upside. Our AI forecast model points to short-term strength (6.26% over two weeks), a medium-term rise (416.5% over three months), and a longer-term gain (342.25% over one year), with expected trading ranges indicating moderate volatility.

Kalaris Therapeutics Inc trades at a P/E ratio of -3.49, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 4.32 trading at moderately above to book value. The P/FCF stands at -4.73, also above market averages.